RT info:eu-repo/semantics/article
T1 Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes
A1 de luis roman, Daniel
AB Objectives To propose the grounds for “diabetic sarcopenia” as a new comorbidity of diabetes, and to establish a musclescreening algorithm proposal to facilitate its diagnosis and staging in clinical practice. Method: A qualitative expertopinion study was carried out using the nominal technique. A literature search was performed with the terms “screening”or “diagnostic criteria” and “muscle loss” or “sarcopenia” and “diabetes” that was sent to a multidisciplinary group of 7experts who, in a face-to-face meeting, discussed various aspects of the screening algorithm. Results: The hallmark ofdiabetic sarcopenia (DS) is muscle mass atrophy characteristic of people with diabetes mellitus (DM) in contrast to thehistological and physiological normality of muscle mass. The target population to be screened was defined as patientswith DM with a SARC-F questionnaire > 4, glycosylated haemoglobin (HbA1C) ≥ 8.0%, more than 5 years since onset ofDM, taking sulfonylureas, glinides and sodium/glucose cotransporter inhibitors (SGLT2), as well as presence of chroniccomplications of diabetes or clinical suspicion of sarcopenia. Diagnosis was based on the presence of criteria of lowmuscle strength (probable sarcopenia) and low muscle mass (confirmed sarcopenia) using methods available in any clinicalconsultation room, such as dynamometry, the chair stand test, and Body Mass Index (BMI)-adjusted calf circumference.DS was classified into 4 stages: Stage I corresponds to sarcopenic patients with no other diabetes complication, and StageII corresponds to patients with some type of involvement. Within Stage II are three sublevels (a, b and c). Stage IIa refers toindividuals with sarcopenic diabetes and some diabetes-specific impairment, IIb to sarcopenia with functional impairment,and IIc to sarcopenia with diabetes complications and changes in function measured using standard tests Conclusion: Diabeticsarcopenia has a significant impact on function and quality of life in people with type 2 diabetes mellitus (T2DM), and it isimportant to give it the same attention as all other traditionally described complications of T2DM. This document aims toestablish the foundation for protocolising the screening and diagnosis of diabetic sarcopenia in a manner that is simple andaccessible for all levels of healthcare.
YR 2024
FD 2024
LK https://uvadoc.uva.es/handle/10324/73685
UL https://uvadoc.uva.es/handle/10324/73685
LA eng
NO Reviews in Endocrine and Metabolic Disorders (2024) 25:651–661
DS UVaDOC
RD 23-feb-2025